CAR-T Cells in Canada; Perspective on How to Ensure We Get Our Value’s Worth

New therapies in a publicly funded healthcare system are first appraised by health technology assessment agencies that provide funding recommendations to the payers. Treatment with Chimeric Antigen Receptor-T cell (CAR-T) therapy is revolutionizing the management of patients with relapsed/refractory...

Descripción completa

Detalles Bibliográficos
Autores principales: Villeneuve, Pierre J. A., Bredeson, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136494/
https://www.ncbi.nlm.nih.gov/pubmed/37185418
http://dx.doi.org/10.3390/curroncol30040305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136494/
https://www.ncbi.nlm.nih.gov/pubmed/37185418
http://dx.doi.org/10.3390/curroncol30040305

Ejemplares similares